#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Ovarian cancer Dementia Alzheimer's type Colorectal cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fatty acid oxidation disorder Cortical dysplasia Hypereosinophilic syndrome Mucopolysaccharidosis I Langerhans cell sarcoma Ischaemic stroke Meningococcal immunisation C3 glomerulopathy Multifocal motor neuropathy Marfan's syndrome Adenovirus infection Breast cancer Anti-neutrophil cytoplasmic antibody positive vasculitis Fibrosarcoma Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Life with Disease Kearns-Sayre syndrome – Treatment Adrenogenital syndrome – Treatment Mucous membrane pemphigoid – Life with Disease Haemolytic uraemic syndrome – Diagnostics Lymphangiosarcoma – Diagnostics Mucopolysaccharidosis I Undifferentiated sarcoma – Life with Disease Breast angiosarcoma metastatic – Life with Disease Rosai-Dorfman syndrome – Trials in Disease More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Padeliporfin Imiquimod Clavulanic Acid Damoctocog Alfa Pegol Methylprednisolone Florbetapir (18F) Human Albumin Solution Satralizumab 64CU-PSMA I&T Anidulafungin Sym024 Doxycycline Hyclate Alks 2680 TUVATEXIB Clomifene Citrate Verapamil Hydrochloride Oregovomab Hydroxocobalamin Pelareorep Sodium Nitroprusside Dihydrate More therapies…

    Learn about Your Condition

    Myxofibrosarcoma Petit mal epilepsy Food allergy Congenital aplastic anaemia Arthroscopy Blood disorder High-grade B-cell lymphoma Adenocarcinoma of colon Retroperitoneal fibrosis Cachexia Anal cancer Extraskeletal ossification Pulmonary sarcoidosis Obsessive-compulsive disorder Thyroid cancer metastatic More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Durvalumab Maintenance Therapy for Frail Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    • Small cell lung cancer limited stage
    Investigated drugs:
    • Durvalumab
    France

  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    • HER2 positive breast cancer
    Investigated drugs:
    • Tucatinib
    • Pertuzumab
    • Trastuzumab
    Austria Belgium Czechia Finland France Germany +6

  • Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    • Pemetrexed Disodium
    • Carboplatin
    • Cisplatin
    Austria France Germany Poland Romania Spain

  • Study of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment

    Not recruiting

    2 1 1 1
    Investigated drugs:
    • Docetaxel
    • Lenvatinib
    • Paclitaxel
    Denmark France Norway Portugal Romania Spain

  • Study on the Effectiveness and Safety of L19TNF and Dacarbazine for Patients with Advanced or Metastatic Soft-Tissue Sarcoma After Previous Treatments

    Not recruiting

    2 1 1 1
    Investigated drugs:
    • Dacarbazine
    • Onfekafusp Alfa
    France Germany Italy Poland Spain

  • Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    • Bladder cancer
    Investigated drugs:
    • Cisplatin
    • Gemcitabine Hydrochloride
    • Nivolumab
    Austria Belgium Finland France Germany Greece +5

  • Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    France

  • Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

    Not recruiting

    2 1 1 1
    Investigated drugs:
    • Binimetinib
    • Encorafenib
    • Ipilimumab
    France Germany Italy The Netherlands Poland Spain

  • Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

    Not recruiting

    3 1 1 1
    Investigated drugs:
    • Everolimus
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    Austria Belgium Czechia France Germany Italy +3
Previous Page
1 … 14 15 16 17 18 19
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!